Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors while in the central nervous process, conolidine modulates alternate molecular targets. A Science Advancements study discovered that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid https://ralstonj764mqs7.livebloggs.com/profile